Area of research
Rheumatology · Immunology
Research interest
Research focused on Systemic mastocytosis and Fibroblast growth factor receptor 1, with related work in Tryptase, Midostaurin, Eosinophilia. Notable publications include 'Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology', 'Avapritinib versus Placebo in Indolent Systemic Mastocytosis', and 'Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis'.
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement
Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group
Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>) Rearrangement (MLN<i>FGFR1</i>): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)